Author: Site Editor Publish Time: 2026-09-17 Origin: Site
On September 10, Yu Haitan, Deputy Secretary of the CPC Jinan Municipal Committee and Mayor of Jinan, visited Bestcomm Pharma to learn about the company’s pharmaceutical R&D capabilities, innovation initiatives, and business development. Representatives from the Jinan Municipal Development and Reform Commission, Jinan Municipal Science and Technology Bureau, Jinan Municipal Bureau of Industry and Information Technology, and Jinan Municipal Bureau of Statistics also participated in the visit. Meng Fanqing, Chairman and General Manager of Bestcomm Pharma, accompanied the delegation and introduced the company’s development and operations.
During the visit to Bestcomm Pharma’s pharmaceutical R&D laboratories, Mayor Yu and the delegation learned about the company’s R&D platforms, technological innovation, intellectual property management, R&D management systems, and scientific and technical talent development. The delegation also visited the company’s analytical laboratories and other R&D facilities.
Meng Fanqing provided an overview of Bestcomm Pharma’s development history, business portfolio, R&D capabilities, and operational performance, highlighting the company’s long-term focus on pharmaceutical research and its continued investment in innovation.
Founded in 2000, Bestcomm Pharma has built an integrated technical platform covering pharmaceutical R&D and industrialization, with capabilities spanning API and finished dosage form development, manufacturing, and bioequivalence (BE) studies. Through years of development, the company has established expertise in key stages of pharmaceutical development, supported by professional technical teams and project management capabilities.
Bestcomm Pharma continues to increase investment in R&D and strengthen its technical talent base. The company currently has more than 600 R&D and technical professionals. To date, Bestcomm Pharma has obtained or supported its partners in obtaining more than 280 drug registration approvals, generic drug consistency evaluation approvals, and API approvals, while continuing to strengthen its technical capabilities in areas including complex formulations and specialty APIs.
Looking ahead, Bestcomm Pharma will remain focused on pharmaceutical R&D and innovation, further strengthening its capabilities in technology development, product innovation, and commercialization of R&D outcomes. By delivering professional and efficient R&D solutions, the company aims to create greater value for its partners and contribute to the sustainable development of the pharmaceutical industry and global healthcare.
